Drugs /

alpelisib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
alpelisib
NCI Definition [1]:
An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for alpelisib

Alpelisib has been investigated in 31 clinical trials, of which 21 are open and 10 are closed. Of the trials investigating alpelisib, 13 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), 11 are phase 2 (10 open), and 3 are phase 3 (3 open).

HER2 Deficient Expression, HER2 Negative, and ER Positive are the most frequent biomarker inclusion criteria for alpelisib clinical trials.

Breast carcinoma, malignant solid tumor, and head and neck squamous cell carcinoma are the most common diseases being investigated in alpelisib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Alpelisib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Alpelisib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating alpelisib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
byl719, phosphoinositide 3-kinase inhibitor byl719, phosphoinositide 3-kinase inhibitor byl719, pi3k inhibitor byl719
Drug Categories [2]:
PI3K inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
PIK3CA
NCIT ID [1]:
C94214

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.